VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (“CNS”) diseases and disorders with high unmet need, this morning announced the appointment of Michael Liebowitz, M.D. to the company’s CNS Clinical and Regulatory Advisory Board. The addition of Dr. Liebowitz seamlessly aligns with VistaGen’s preparation for its pivotal phase 3 development of PH94B. PH94B is set to be the first fast-acting, on-demand treatment for social anxiety disorder (“SAD”), an incapacitating social phobia affecting roughly 15 million American adults. “Dr. Liebowitz has done life-changing work in addressing the widespread affliction of SAD. He has not only conducted many clinical trials in SAD, but he also developed the Liebowitz Social Anxiety Scale, or LSAS, which is widely-used as a primary outcome measure in clinical research on SAD, as well as for evaluation in clinical practice. Most importantly, we share his passion in helping patients. His decades of expertise will add enormous value to our efforts to provide a new and more effective treatment to the millions of people who are suffering from this debilitating condition,” Mark Smith, M.D., Ph.D., Chief Medical Officer of VistaGen stated in the news release.
To view the full press release, visit http://nnw.fm/4Z0wh
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. For more information, visit the company’s website at www.VistaGen.com.
More from NetworkNewsBreaks
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com